VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

NCT01830465 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Non Hodgkin's Follicular Lymphoma

Interventions

DRUG: Bortezomib (VELCADE)
DRUG: Rituximab

Sponsor

Gruppo Italiano Studio Linfomi